pathophysiology of rheumatoid arthritis &...
TRANSCRIPT
![Page 1: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/1.jpg)
Pathophysiology of Rheumatoid Arthritis & Osteoarthritis
Atul Deodhar MDAtul Deodhar MDAssociate Professor of MedicineAssociate Professor of Medicine
Medical Director, Rheumatology ClinicsMedical Director, Rheumatology ClinicsOregon Health & Science UniversityOregon Health & Science University
November 15, 2007
![Page 2: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/2.jpg)
A Superficial and Informal Overview of a Patient with ‘Aches & Pains’
• Musculoskeletal pain• Rheumatoid arthritis• Osteoarthritis
![Page 3: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/3.jpg)
Within Joint“Arthritis”
Subchondral boneCartilage
Synovial fluidSynovium
Around Joint“Peri-articular”
MuscleTendon
TenosynoviumEnthesis
BursaLigament
Away From Joint“Non-articular”
MuscleBone
Away fromMusculoskeletal
System“Referred”
VisceralNeurological
![Page 4: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/4.jpg)
Rheumatoid Arthritis• Chronic• Inflammatory• Polyarticular• Symmetrical• Involves PIP/MCP/Wrist/MTP• Synovial Proliferation• Erosive
![Page 5: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/5.jpg)
• History– rapid onset– waxing/waning course– red/hot joint – inflammatory pain: use, rest, night– profound, prolonged morning stiffness– systemic findings
• Physical examination– red/hot joint (but inflammatory arthritis uncommonly
has red/hot joints)– SYNOVITIS
Inflammatory Arthritis
![Page 6: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/6.jpg)
RA - Inflammatory Arthritis
• Onset in days, weeks, months; not “years”
• Waxing/waning course• Inflammatory pain
– pain with use– pain at rest– night pain
• Morning stiffness: profound/prolonged
• Systemic inflammation– symptoms– signs– labs
• Physical exam– inflammatory joint fluid– “synovitis”
![Page 7: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/7.jpg)
Stages of RAEarly Intermediate Late
Courtesy of J. Cush, 2002.
![Page 8: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/8.jpg)
Seve
rity
(arb
itrar
y un
its)
Duration of Disease (years)
RA Progression RA Progression
Graph: Adapted from Kirwan JR. J Rheumatol. 2001;28:881-886.
0 5 10 15 20 25 30
Early RA Intermediate LateInflammationDisabilityRadiographs
![Page 9: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/9.jpg)
The Synovial Membrane
Normal synovial membrane, photomicrograph
![Page 10: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/10.jpg)
Pathophysiology of RA
Synovitis, villous, gross (left) and photomicrograph (right)
![Page 11: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/11.jpg)
![Page 12: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/12.jpg)
Pathogenesis of RABreedveld FC. J Rheumatol. 1998;25:3-7.
antigen
HLA class II molecule
Antigen presenting cellAntigen presenting cell
T cell
![Page 13: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/13.jpg)
APC CD4+ T cell
MHC TCRPeptide
B Cells Synoviocytes Adhesion
Immunobiology of Rheumatoid Arthritis
IL-1TNFαIL-6TGFβ
IFNγIL-2IL-4TNFβ
![Page 14: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/14.jpg)
Cytokine producing cell
Inducing stimulus
Cytokine Cytokine genegene
Gene Gene activationactivation
Biological response
Receptor
Cytokines
Cytokine activated cell
Cytokines• Secreted polypeptides
• Control
•cellular function
•differentiation
•intercellular communication
•Important mediators of immune & inflammatory responses
![Page 15: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/15.jpg)
The Summary of RA Pathology
Choy EHS, Panayi GS.NEJM 2001;344:907-916
TNF-αIL-1IL-6
IFN-γIL-12
IL-4IL-10
Macrophage
RF
IL-4IL-6IL-10
Plasmacell
B cell
Interferon-γ
Th0
Th2
Synovium
OPGL
CD4 + T cell
CD69 CD11
CD11CD69
Osteoclast FibroblastChondrocyte
Production of metalloproteinases andother effector molecules
Migration of polymorphonuclear cells
Erosion of bone and cartilage
![Page 16: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/16.jpg)
Choy EHS, Panayi GS. NEJM 2001;344:907-916.
Disease Progression
Capillary Formation
HyperplasticSynovialMembrane
HypertrophicSynoviocyte
Neutrophils
T Cells B Cells
Early Rheumatoid Arthritis
Established Rheumatoid Arthritis
Synovial Villi
ExtensiveAngiogenesis
Plasma Cell
PannusEroded Bone
Neutrophils
CartilageCapsule
Bone
Synovial Membrane
Synoviocytes
Normal Joint
![Page 17: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/17.jpg)
TNF - αIL-1IL-6
sTNFRIL-1rasIL-1RIL-4IL-11
Cytokine Disequilibrium in RA
Pro-inflammatory Anti-inflammatory
![Page 18: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/18.jpg)
Synthesis and Actions of TNFα
![Page 19: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/19.jpg)
RHEUMATOID ARTHRITIS:Role of TNF-α
TNF- α is a potent cytokine that stimulates a variety of pro-inflammatory cellsTNF- α is produced mainly by monocytes & macrophagesTNF- α is a major contributor to the inflammatory and destructive changes that occur in RABlockade of TNF-α results in reduction in the levels of other pro-inflammatory cytokines, such as IL-1, IL-6, and IL-8
Choy EHS, Panayi GS. N Engl J Med. 2001;344:907-916.Feldmann M et al. Annu Rev Immunol. 1996;14:397-440.
![Page 20: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/20.jpg)
RA: Extra-articular Manifestations
• Systemic sx/signs• Anemia of chronic
disease• Nodules• Vasculitis
– hypersensitivity– PAN-like
• Neuropathy
• Ophthalmologic• Pulmonary
– fibrosis– nodules– effusions
• Felty’s syndrome• Sjogren’s syndrome
![Page 21: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/21.jpg)
Rheumatoid Factor
NormalYoungOld
Non-rheumatic disease
Rheumatic diseaseRAOther
% of patients with +RF
0.7-210-24
0-50
850-74
![Page 22: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/22.jpg)
Rheumatoid Factor• Positive RF
– Does NOT diagnose RA by itself– If “high titer”
• increased risk of RA• more severe disease
– Little change in titer with course• Negative RF
– Does NOT exclude RA
![Page 23: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/23.jpg)
Goals in Treating RA
• Treat current symptoms: pain, stiffness, swelling, decreased range of motion, function
• Prevent structural damage• Improve long term outcome: disability,
death
![Page 24: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/24.jpg)
Treatment of RA• Education• PT/OT, Vocational rehabilitation• NSAIDs• Disease Modifying Anti-Rheumatic Drugs (DMARD)• Biologic therapy
In some patients• Intra-articular, I/M or oral Steroids• Surgery for pain/function improvement, deformity
![Page 25: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/25.jpg)
All patients with RA should be treated with DMARDs as soon as diagnosis is made
• Gold, d-Penicillamine• Hydroxychloroquine, Minocycline, Sulfasalazine• Methotrexate, Azathioprine, Leflunomide• Cyclosporine, Cyclophosphomide• TNF inhibition: etanercept/infliximab/adalimumab• IL-1 receptor antagonist: anakinra• Anti-CD 20 monoclonal antibody: Rituximab• Co-stimulation blocking agents: Abatacept
![Page 26: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/26.jpg)
Toxicities of DMARDs• Hydroxychloroquine
(Plaquenil)
– retinal
• Sulfasalazine (Azulfidine)
– photosensitivity– GI (dyspepsia)– leukopenia
• Gold (Myochrysine, Solganal)
– rash/oral ulcers– thrombocytopenia– proteinuria
• Methotrexate– GI/rashes– hematologic– lung– liver (cirrhosis)
• Leflunomide (Arava)– GI/diarrhea– hematologic/liver/skin
• Azathioprine (Imuran)
– leukopenia/infection– ? lymphoma
![Page 27: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/27.jpg)
Prednisone in RAPrednisone may be the most effective medical
therapy for RAPrednisone may be the most toxic medical therapy
for RAWhen is prednisone indicated in RA?
– “Bridging Therapy”: providing some control while DMARDs are beginning to work
– Extra-articular disease– RA in the elderly: PMR-like; low-dose prednisone
vs. high-dose NSAIDs
![Page 28: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/28.jpg)
Inhibition of Cytokines
Choy EHS, Panayi GS. N Engl J Med. 2001;344:907-916.
Activation ofanti-inflammatory pathways
Anti-inflammatorycytokine
Suppression ofinflammatorycytokines
Neutralization of cytokines
Soluble receptor
Monoclonal antibody
No signal
Receptor blockade
Monoclonal antibody
Receptor antagonist
No signal
Inflammatory cytokine
Normal interaction
Cytokine receptor
Inflammatory signals
![Page 29: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/29.jpg)
Soluble Receptor Neutralization of TNFα
022900.1 Hendricks 29
Etanercept(Enbrel)
![Page 30: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/30.jpg)
Soluble receptor constructs bind & neutralize soluble TNF-α & β, but not membrane-bound TNF-α
Soluble TNF-β
Soluble TNF-α
Receptor-bound TNF-α
Soluble receptor
construct
![Page 31: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/31.jpg)
Antibody Neutralization of TNFαInfliximab(Remicade)
Adalimumab(Humira)
![Page 32: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/32.jpg)
Monoclonal Antibodies Bind and Neutralize Both Soluble and Membrane-bound TNF-α
![Page 33: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/33.jpg)
B Cells May Act at Multiple Sites in the Autoimmune/Inflammatory Process
• B cells play a role in the pathogenesis of RA– Antigen presentation &
T-cell activation– Production of pro-
inflammatory cytokines
– Production of RF & other autoantibodies
![Page 34: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/34.jpg)
Rituximab: anti CD20 mab
Kehrl et al. Immunol Today. 1994;15:432; Golay et al. Blood. 2000;95:3900.
• Genetically engineered chimericmurine/human monoclonal antibody to CD20
• IgG1 kappa immunoglobulin, murine light & heavy chain variable sequence & human constant region sequence
• Selectively binds CD20 molecule with high affinity (Kd8.0 nM)
• Half life: 18-21 days
![Page 35: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/35.jpg)
RituximabMechanisms of Action
ADCC = antibody-dependent cell mediated cytotoxicity.CDC = complement-dependent cytotoxicity.Golay et al. Blood. 2000;95:3900; Reff et al. Blood. 1994;83:435; Byrd et al. Blood. 2002;99:1038.
Rituximab
B cell
Apoptosis
Macrophage,monocyte, ornatural killer cell
FcγRII, FcγRIII
Cell lysis
CD20
ADCC
CDC
CD20
Cell lysis
MAC
Complement activation (C1qC1rC1s)
![Page 36: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/36.jpg)
B7.1 (CD80) or B7.2 (CD86) on APC & CD28 on T cell
First Signal
Second ‘Co-stimulatory’Signal
Activation of Naïve T cellRequires two signals
1. Peptide/MHC complexplus CD4
2. Co-stimulatory
![Page 37: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/37.jpg)
T cell activation through CD28 leads to increased expression ofT cell activation through CD28 leads to increased expression ofCTLACTLA--4 (cytotoxic T lymphocyte associated antigen 4) on T cell 4 (cytotoxic T lymphocyte associated antigen 4) on T cell surface, an alternative receptor for B7surface, an alternative receptor for B7
CTLACTLA--4 has higher affinity for B74 has higher affinity for B7CTLACTLA--4 down4 down--regulates T cell activationregulates T cell activation
![Page 38: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/38.jpg)
Abatacept Mechanism of Action
![Page 39: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/39.jpg)
Biologic DMARDsAnakinraInfliximabEtanercept
HumanChimericHumanRecombinconstruct
Type I IL-1R
TNF-αTNF-αPrimary binding target
4-6 hrs8-10 d4.3 dHalf-life
Human
TNF-α
10-20 d
IL-1RaTNF-αmAb
sTNFR construct
Class TNF-αmAb
100 mg/d sc
3-10 mg/kgQ4-8 wk iv + MTX
25 mg sc2x/wk
Admin40 mg sc eow
Adali-mumab Rituximab
CD-20 mAb
Chimeric
15-21 d 13 d
Abatacept
CTLA-4 construct
Human
CD-80 CD-86
CD-20B Cell
1000 mg iv d1 & 15
10 mg/kg Q4 wk
![Page 40: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/40.jpg)
New Biologics to Treat RA on the Horizon
• Certolizumab (Cimzia): Humanized PEG-ylatedmonoclonal antibody against TNF (only FAB, no Fc)
• Tocilizumab (Actimra): humanized monoclonal antibody to IL-6 receptor
• Atacicept and Belimumab: new B cell directed agents
![Page 41: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/41.jpg)
Rheumatoid Arthritis• Chronic• Inflammatory• Polyarticular• Symmetrical• Arthritis: PIP/MCP/Wrist/MTP• Synovial Proliferation, Erosive• Needs immediate treatment with DMARDs• Newer anti-cytokine treatments are very effective
![Page 42: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/42.jpg)
![Page 43: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/43.jpg)
• History– slow steady progression– no “believable” red/hot joints– mechanical pain: ↑ use, ↓ rest/night– no profound/prolonged morning stiffness– no systemic findings
• Physical exam– swelling:
• effusion/osteophytes/ligaments– crepitus/grating– local joint line tenderness
Non-inflammatory Arthritis
![Page 44: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/44.jpg)
Osteoarthritis – Risk Factors
• Age• Gender – women > men• Genetic predisposition• Trauma• Obesity• Quadriceps muscle weakness• Heavy physical activity
![Page 45: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/45.jpg)
Osteoarthritis• Primary/nodal OA:
– DIP: Heberden’s nodes– PIP: Bouchard’s nodes– 1st CMC
• Secondary OA– knee/hip– trauma
• Spinal OA/degenerative disk disease
![Page 46: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/46.jpg)
Pathophysiology
• Primarily a disease of cartilage• Cartilage made up of water, proteoglycans and
collagen• Mechanical stress across joints may initiate
process followed by cartilage degradation• Ultimate loss of joint architecture
![Page 47: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/47.jpg)
Osteoarthritis = Joint failureOsteoarthritis = Joint failure
![Page 48: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/48.jpg)
Osteoarthritis
• Not just “degeneration”• Osteoarthritis is an “active” process
– Ineffective repair– Chrondrocyte dysfunction– Protease activation (MMP, Collagenase)– Cytokine/growth factor elaboration
• “Active” processes can be treated (?)
![Page 49: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/49.jpg)
Osteoarthritis• Pathogenesis:
– genetic factors– altered biomechanical forces
(abnormal pressure to normal cartilage or normal pressure to abnormal cartilage)
– pre-existing diseases of the hip/knee• Management designed to reduce symptoms and
improve function
![Page 50: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/50.jpg)
Radiographic Changes in OA
• Joint space narrowing• Subchondral sclerosis• Subchondral cysts• Osteophytes
![Page 51: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/51.jpg)
![Page 52: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/52.jpg)
![Page 53: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/53.jpg)
![Page 54: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/54.jpg)
Osteoarthritis of the KneeACR Classification Criteria
• Knee pain and radiographic osteophyte and at least 1 of the following:– age > 50 years– morning stiffness < 30 minutes– crepitus on motion
![Page 55: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/55.jpg)
![Page 56: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/56.jpg)
![Page 57: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/57.jpg)
Clinical Findings in Osteoarthritis• Arthritis: pain with use, limited/painful ROM• Non-inflammatory arthritis:
– Slowly progressive– Mechanical pain: ↑ use, ↓ rest/night– Little morning stiffness– “Gelling”– Crepitus/grating– Joint enlargement: bone, effusion, ligaments– Joint line tenderness
![Page 58: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/58.jpg)
Goals in Treating Osteoarthritis
• Treat pain• Protect joint• Stabilize/improve function• ? Prevent further deterioration
![Page 59: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/59.jpg)
Treatment
• Pharmacologic vs Non-pharmacologic • Two Primary Goals
– Treat pain– Improve function
![Page 60: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/60.jpg)
Medical Management of OAACR Guidelines
• Original Publication in 1995• Ad hoc subcommittee established 1998• ‘Evidence based medicine’ approach• New guidelines published Sept 2000
Arthritis Rheum 2000;43:1905-1915
![Page 61: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/61.jpg)
ACR Guidelines 2000Non-pharmacological Therapy
• Patient Education, Self management programs, social support
• Weight loss if overweight• PT: aerobic strengthening exercises, ROM• Assisted device, footwear, insole, bracing• OT: joint protection, energy conservation
Arthritis Rheum 2000;43:1905-1915
![Page 62: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/62.jpg)
Non-pharmacologic Treatment
• Exercise – strengthening, flexibility, aerobic• Weight loss• Orthotics/assistive devices• Alternative remedies
– Glucosamine/chondrotin– Vitamin C/D (low intake- risk of progression)– Herbals
![Page 63: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/63.jpg)
Exercise therapy - goals
• Decreases pain• Improves function
– Posture– Gait stability– May reduce falls
![Page 64: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/64.jpg)
Exercise therapy
• Exercise program should be tailored to individual patient
• Flexibility, strength and endurance• Goal oriented program• Caution for musculoskeletal injury• Contraindications to exercise – heart disease, poorly
controlled hypertension
![Page 65: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/65.jpg)
ACR Guidelines 2000Pharmacological Therapy: 1
• Oral– Acetaminophen– COX-2 specific inhibitor– Non-selective NSAID plus misoprostol/PPI– Non-acetylated salicylate– Other pure analgesics:
• Tramadol• Opioids
![Page 66: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/66.jpg)
NSAIDs Overview• Consumption: 30 million in US• Sales: $6 billion/year worldwide• Uses: the aches and pains of life• Problems: GI, renal, platelets• Dyspepsia: common• Estimated deaths: > 10,000/year
in US, due to ulcers and bleeding
![Page 67: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/67.jpg)
Described an extract of seminal fluid which caused
uterine contraction -“Prostaglandin”
Nobel Prize in 1970 for describing the release of nor-adrenaline from sympathetic nerves
Bengte Samuelson Sune Bergstrom John Vane
Nobel Prize in 1982 forNobel Prize in 1982 for““their discoveries concerning prostaglandinstheir discoveries concerning prostaglandins””
Ulf von ULER
![Page 68: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/68.jpg)
Cell Membrane Phospholipids
Arachidonic acid
PGHPGH22
PGD2 PGE2 PGF2α PGI2 TXA2
Cyclooxygenase
Phospholipase A2
![Page 69: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/69.jpg)
Number of Deaths 20 NSAID Damage Compared with Other Causes: 1997*
20197
16685 16500
10503
5338 4441
14370
5,000
10,000
15,000
20,000
25,000
Leukemia HIV NSAIDs GI**
Multiplemyeloma
Asthma Cervicalcancer
`Hodgkin'sDisease
Nu m
b er o
f Dea
t hs
Causes of Death*National Center for Health Statistics, 1998
Singh et al. J Rheum 1999; 26(Suppl 56):18-24
![Page 70: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/70.jpg)
Mechanism of Action of COX-2 Selective NSAIDs
Normal Physiologic Stimulus Inflammatory Stimulus
•• GI protectionGI protection•• Platelet AggregationPlatelet Aggregation•• Regulation of blood flowRegulation of blood flow•• Kidney functionKidney function•• Sensory processingSensory processing
•• InflammationInflammation•• PainPain•• FeverFever
ARACHIDONIC ACID
COX-1 COX-2
ProstaglandinsSelectiveCOX-2Inhibitors
Prostaglandins
Constitutive Inducible
![Page 71: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/71.jpg)
CH3
F3CN N
SO
O NH2
S
CH3
O
O
O
O
Celecoxib Rofecoxib Valdecoxib
NO
CH3
SNH2
OO
COX-2 Specific Inhibitors:Chemical Structures
![Page 72: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/72.jpg)
Merck Announces Voluntary Worldwide Withdrawal of VIOXX®
Merck & Co. CEO Raymond V. Gilmartin announcing the withdrawal of Vioxx
WHITEHOUSE STATION, N.J., Sept. 30, 2004—Merck & Co., Inc. today announced a voluntary worldwide withdrawal of VIOXX® (rofecoxib), its arthritis and acute pain medication. The company’s decision, which is effective immediately, is based on new, three-year data from a prospective, randomized, placebo-controlled clinical trial, the APPROVe(Adenomatous Polyp Prevention on VIOXX) trial
![Page 73: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/73.jpg)
COXCOX--2 Inhibition & MI2 Inhibition & MI
Arachidonic acidArachidonic acid
PGIPGI22TXATXA22
Platelet AggregationPlatelet Aggregation VasodilatationVasodilatation
COXCOX--22COXCOX--11
HypothesisHypothesis
XXX
![Page 74: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/74.jpg)
ACR Guidelines 2000Pharmacological Therapy: 2
• Intra-articular:– Glucocorticoids– Hyaluronan
• Topical– Capsaicin– Methylsalicylate
![Page 75: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/75.jpg)
Viscosupplementation
••SynviscSynvisc®® and and HyalganHyalgan®®
••Synthetic Synthetic hyaluronichyaluronic acidacid
![Page 76: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/76.jpg)
Viscosupplementation
•• Improve lubrication, nutrition, and function of Improve lubrication, nutrition, and function of articular cartilagearticular cartilage
•• Efficacy is variableEfficacy is variable•• Patients with early OA and moderate symptoms Patients with early OA and moderate symptoms
benefit most (not indicated with benefit most (not indicated with ‘‘bonebone--onon--bonebone””))
![Page 77: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/77.jpg)
“Alternative” Therapies
•• Glucosamine/chondroitinGlucosamine/chondroitin•• SAMeSAMe•• MagnetsMagnets•• AntiAnti--inflammation dietsinflammation diets•• DMSODMSO
![Page 78: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/78.jpg)
Alternative MedicationsCAUTIONS
• NOT FDA regulated• Unclear effective dosage • Minimal data on toxicity – especially with long
term use• Not currently recommended until further studies
are available
![Page 79: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/79.jpg)
•• Widely used in Europe for > 10 yearsWidely used in Europe for > 10 years•• Very few side effects (diabetics should watch Very few side effects (diabetics should watch
their blood sugars)their blood sugars)•• Not FDA approved, so no strict quality controlNot FDA approved, so no strict quality control
Glucosamine/Chondroitin
![Page 80: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/80.jpg)
Glucosamine• Found in normal cartilage where they are believed
to play a role in formation & repair• Sulfate, hydrochloride, N-acetyl, chlorhydrate• ‘Disease Modifying’ or ‘Anti-inflammatory’• Source for supplements: shells of crabs, lobsters
and shrimp
![Page 81: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/81.jpg)
Chondroitin
• Limited studies compared to Glucosamine• Derived from cattle, only 10% absorbed orally• ? Anti-inflammatory, ? Disease Modifying• May improve pain & function when compared
with placebo
![Page 82: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/82.jpg)
•• The The sulfatesulfate form (rather than chloride) is form (rather than chloride) is recommended recommended
•• Optimal dose is Optimal dose is unkownunkown –– in studies, patients in studies, patients took 1500mg/day took 1500mg/day glucosamineglucosamine and 1200mg/day and 1200mg/day of of chondroitinchondroitin
•• If no improvement after 3 months, save your If no improvement after 3 months, save your moneymoney
Glucosamine/chondroitin
![Page 83: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/83.jpg)
SAMe
•• SS--adenosylmethionineadenosylmethionine•• Molecule involved in a number of metabolic Molecule involved in a number of metabolic
processesprocesses•• AntiAnti--depressant effect in patients with RAdepressant effect in patients with RA•• AntiAnti--inflammatory effects in animal studiesinflammatory effects in animal studies•• Analgesic effects in patients with mild to Analgesic effects in patients with mild to
moderate OA moderate OA –– as effective as NSAIDs in some as effective as NSAIDs in some studies studies
![Page 84: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/84.jpg)
•• No serious side effectsNo serious side effects•• Mechanism of action unknown (?antiMechanism of action unknown (?anti--depressant depressant
activity)activity)•• Dose used in studies: 200 Dose used in studies: 200 –– 400 mg 3 times daily400 mg 3 times daily•• May take a month to have an effectMay take a month to have an effect•• Renewed interest of late (possibly in the wake of Renewed interest of late (possibly in the wake of
glucosamineglucosamine……))
SAMe
![Page 85: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/85.jpg)
Others
• Avocado and soybean unsaponifiables – action unknown
• Acupuncture - ??• Surgery - joint replacement is indicated for
severe pain, not for functional improvement
![Page 86: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/86.jpg)
![Page 87: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/87.jpg)
![Page 88: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/88.jpg)
Pathophysiology
• Primarily a disease of cartilage• Cartilage made up of water, proteoglycans and
collagen• Mechanical stress across joints may initiate
process followed by cartilage degradation• Ultimate loss of joint architecture
![Page 89: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/89.jpg)
Osteoarthritis = Joint failureOsteoarthritis = Joint failure
![Page 90: Pathophysiology of Rheumatoid Arthritis & Osteoarthritisdrtedwilliams.net/cop/761/761OARAPathophysiology.pdf · Pathophysiology of Rheumatoid Arthritis & Osteoarthritis Atul Deodhar](https://reader038.vdocument.in/reader038/viewer/2022102919/5a73c4557f8b9a1b688b6010/html5/thumbnails/90.jpg)
Treatment of OA• Correct diagnosis• Psychological factors• Physical factors
– Weight loss– Exercise– Formal PT– Neoprene sleeves– Other braces– Canes, etc
• Analgesia– Acetaminophen– NSAIDs– Opioids
• Intraarticular injection– Steroids– Hyaluronic acid
• Surgery